-
1 Comment
Tibet Rhodiola Pharmaceutical Holding Co is currently in a long term downtrend where the price is trading 4.8% below its 200 day moving average.
From a valuation standpoint, the stock is 9.7% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 8.7.
Tibet Rhodiola Pharmaceutical Holding Co's total revenue rose by 18.1% to $384M since the same quarter in the previous year.
Its net income has increased by 27.8% to $94M since the same quarter in the previous year.
Finally, its free cash flow grew by 1.8% to $99M since the same quarter in the previous year.
Based on the above factors, Tibet Rhodiola Pharmaceutical Holding Co gets an overall score of 4/5.
| ISIN | CNE000000ZW7 |
|---|---|
| Sector | Healthcare |
| Exchange | SHG |
| CurrencyCode | CNY |
| Industry | Drug Manufacturers - Specialty & Generic |
| Market Cap | 12B |
|---|---|
| PE Ratio | 11.53 |
| Target Price | 59.2 |
| Beta | 1.43 |
| Dividend Yield | None |
Tibet Rhodiola Pharmaceutical Holding Co. produces and sells pharmaceuticals in China and internationally. The company offers biological products, tibetan medicine, chinese medicine, and chemical medicine products. It also offers capsules, preparations, granules, and coatings for cardiovascular, cerebrovascular, hepatobiliary, sprains and contusions, rheumatism, rheumatoid arthritis, colds, etc. Tibet Rhodiola Pharmaceutical Holding Co. was founded in 1999 and is based in Lhasa, China.
Learn MoreHere's how to backtest a trading strategy or backtest a portfolio for 600211.SHG using our backtest tool. PyInvesting provides the backtesting software for you to backtest your investment strategy. Our backtest software is written using Python code and allows you to backtest stock, backtest etf, backtest options, backtest crypto and backtest forex online. Our backtesting Python framework is highly robust and gives you a realistic simulation of how your strategy would have performed in the past using backtest data.
© PyInvesting 2025
